Table 3 Group B (LHRH agonist) lipid profile data
From: The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma
Baseline(A) | 6 month(B) | 12 month(C)* | 24 month(D)* | p value | |
|---|---|---|---|---|---|
Total cholesterol | 173.1 ± 21.3 | 193.8 ± 32.4 | 171.5 ± 20.8 | 170.5 ± 21.1 | < 0.0001 |
Triglycerides | 109.1 ± 31.4 | 133.4 ± 31.3 | 114 ± 31.1 | 110.2 ± 31.6 | < 0.001 |
HDL-cholesterol | 49.2 ± 7.3 | 47.2 ± 7.3 | 47.4 ± 8.8 | 47.6 ± 9.4 | 0.69 |
LDL-cholesterol | 103.9 ± 19.6 | 125.8 ± 28.9 | 103.1 ± 20.8 | 102.3 ± 22.3 | < 0.0001 |
VLDL-cholesterol | 20 ± 4.1 | 23.1 ± 5.1 | 21.9 ± 3.4 | 20.6 ± 4.1 | 0.006 |